Last reviewed · How we verify
Dimenhydrinate (DIMENHYDRINATE)
Dimenhydrinate, marketed by Alra, is an antihistamine primarily indicated for motion sickness, competing in a well-established class of drugs. Its key strength lies in its mechanism of action, effectively blocking histamine to alleviate nausea and vomiting, with a key composition patent expiring in 2028. The primary risk is the strong presence of off-patent competitors such as diphenhydramine and clemastine, which are widely available generics, potentially eroding market share.
At a glance
| Generic name | DIMENHYDRINATE |
|---|---|
| Sponsor | Alra |
| Drug class | dimenhydrinate |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1972 |
Approved indications
- Motion sickness
Common side effects
Key clinical trials
- Evaluation of the Effect of the Toothpaste on Delicate Gums (NA)
- Fluoride in Saliva After Use of Fluoride Toothpastes Followed by Fluoride Mouthrinses (EARLY_PHASE1)
- Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
- Evaluation of the Whitening Effect in Subjects After Professional Tooth Cleaning Procedure (NA)
- Porcine Derma for Soft Tissue Augmentation Around Implants (NA)
- Evaluation of the Performance and Safety of a Linear Hyaluronic Acid-Based Medical Device in the Treatment of Surgical Wounds in the Oral Cavity. (NA)
- Effects of a Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment (NA)
- ACT Therapy for HF Migraine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimenhydrinate CI brief — competitive landscape report
- Dimenhydrinate updates RSS · CI watch RSS
- Alra portfolio CI